banner
Together we Drive the Future

연사



PLENARY KEYNOTE SPEAKERS
John Dunlop

John Dunlop
Vice President, Neuroscience
Amgen
John Dunlop
Vice President, Neuroscience
Amgen
 
Dennis A. Steindler

Dennis A. Steindler
Senior Scientist and Director, Neuroscience and Aging Laboratory
JM USDA HNRCA, The Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University
Dennis A. Steindler
Senior Scientist and Director, Neuroscience and Aging Laboratory
JM USDA HNRCA, The Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University
 
About Speaker:

Dr. Steindler previously was the Joseph J. Bagnor/Shands Professor of Medical Research in the Department of Neurosurgery of the University of Florida College of Medicine and the McKnight Brain Institute of the University of Florida. He did his undergraduate work at the University of Wisconsin Madison and received his doctorate in anatomy studying neurobiology from the University of California, San Francisco. After postdoctoral research at the Max-Planck-Institute for Biophysical Chemistry in Germany, Dr. Steindler continued his studies of brain development and disease, repair and cancer as a faculty member including an endowed professorship in the Department of Neurosurgery at the University of Florida College of Medicine where he also became the Executive Director of the Evelyn F. and William L. McKnight Brain Institute.
Dr. Steindler's research is focused on the growth, transplantation and therapeutic applications of normal and cancerous stem cells, many of which his lab was the first to clone and characterize. Recent studies in his lab focus on testing stem cell biology and regenerative medicine therapeutics in models of brain cancer, Parkinson's and Alzheimer's Disease. In addition to creating patient- and disease-specific avatars for the testing of new molecular and biologic therapies, novel cell culture assays and biomarker screenings, including exosomal analysis, are used to screen for therapeutics including omically-designed combinations of nutrient phytocompounds and other precision medicine therapeutics.
He has served on or retains positions on government grant review panels as well as the editorial boards of the journals: The Journal of Neuroscience, GLIA, Experimental Neurology, The Journal of Neurocytology, Gene Expression, Developmental Brain Research, Brain Research, and The Journal of Parkinson's Disease. He also has held or holds positions on the Scientific Advisory Boards of the Michael J. Fox Foundation for Parkinson's Research and the Accelerate Brain Cancer Cure Foundation. He has issued patents in the stem cell biology and regenerative medicine field, and has co-founded three biotech companies.

Rudolph Tanzi

Rudolph Tanzi
Vice-Chair Neurology Research
Massachusetts General Hospital, Harvard Medical School
Rudolph Tanzi
Vice-Chair Neurology Research
Massachusetts General Hospital, Harvard Medical School
 
About Speaker:

Dr. Rudolph Tanzi is the Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.
Dr. Tanzi received his B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School in 1990. In his research achievements, Dr. Tanzi served on the team that was the first to find a disease gene ((Huntington's disease) using human genetic markers, helping to launch the field of neurogenetics.
Dr. Tanzi co-discovered all three early-onset familial Alzheimer's disease genes and identified several others as leader of the Alzheimer's Genome Project supported by the Cure Alzheimer's Fund, for which Dr. Tanzi also serves Chair of the Research Consortium. He also discovered the Wilson's disease gene and several other neurological disease genes. He and his team used Alzheimer's genes and human stem cells to create "Alzheimer's-in-a-Dish". This is a three-dimensional human stem cell-derived neural culture system that is the first to recapitulate both pathological hallmarks of Alzheimer's disease: plaques and tangles. This model has made drug screening for Alzheimer's disease considerably faster and more effective. Dr. Tanzi has developed several novel therapies for AD including gamma secretase modulators aimed at plaque pathology. Most recently, Dr. Tanzi and his team have discovered that beta-amyloid, the main component of senile plaques, may play a role in the innate immune system of the brain operating as an anti-microbial peptide, suggesting a possible role for infection in the etiology and pathogenesis of AD.
Dr. Tanzi has published over 500 research papers and has received the highest awards in his field, including the Metropolitan Life Foundation Award, Potamkin Prize, Ronald Reagan Award, Silver Innovator Award, and the Smithsonian American Ingenuity Award, the top national award for invention and innovation. He serves on dozens of editorial boards and scientific advisory boards and was named to TIME magazine's list of TIME100 Most Influential People in the World (2015). He co-authored the popular trade books "Decoding Darkness", New York Times bestseller, "Super Brain", and international bestseller "Super Genes".

Neurodegenerative Diseases Research & Development
DISTINGUISHED SPEAKERS
Robert Bell

Robert Bell
Senior Principal Scientist, Neurovascular Biology Lab Head
Pfizer
Robert Bell
Senior Principal Scientist, Neurovascular Biology Lab Head
Pfizer
 
Gabriela Chiosis

Gabriela Chiosis
Professor
MSKCC
Gabriela Chiosis
Professor
MSKCC
 
Errol De Souza

Errol De Souza
President & Chief Executive Officer
Neuropore Therapies
Errol De Souza
President & Chief Executive Officer
Neuropore Therapies
 
Michelle Hastings

Michelle Hastings
Associate Professor of Cell Biology and Anatomy
Rosalind Franklin University/Chicago Medical School
Michelle Hastings
Associate Professor of Cell Biology and Anatomy
Rosalind Franklin University/Chicago Medical School
 
Stephen Moriarty

Stephen Moriarty
Director, Neurosciences
SRI International
Stephen Moriarty
Director, Neurosciences
SRI International
 
Katrina Paumier

Katrina Paumier
Assistant Professor of Neurology
Washington University School of Medicine
Katrina Paumier
Assistant Professor of Neurology
Washington University School of Medicine
 
Francisco Quintana

Francisco Quintana
Associate Professor of Neurology
Harvard Medical School
Francisco Quintana
Associate Professor of Neurology
Harvard Medical School
 
About Speaker:

Francisco J. Quintana, PhD is an Associate Professor of Neurology at the Center for Neurologic Diseases, at Brigham and Women's Hospital, Harvard Medical School, and an Associate Member at the Broad Institute of Harvard and MIT.

Dr. Quintana, a graduate of the University of Buenos Aires (1999, Argentina), obtained his PhD in immunology at the Weizmann Institute of Science (2004, Israel). He received postdoctoral training at the Weizmann Institute of Science and at Harvard Medical School. In 2009, Dr. Quintana joined the faculty of Harvard Medical School.

Dr. Quintana's research investigates signaling pathways that control the immune response and neurodegeneration, with the ultimate goal of identifying novel therapeutic targets and biomarkers for immune-mediated disorders. Dr. Quintana has published over 140 peer reviewed articles and book chapters. In addition, Dr. Quintana's research has resulted in multiple patents which have been the foundation of three companies: ImmunArray Ltd, Alma Bio Therapeutics and AnTolRx Inc.

Dr. Quintana is the recipient of the Lady Anne Chain Prize for Academic Excellence and Scientific Achievements, the Junior Investigator Award from the National Multiple Sclerosis Society, the Pathway to Independence Award of the National Institute of Allergy and Infectious Diseases, the Award for Outstanding Research Achievement form Nature Biotechnology and the Tecan Award for Innovation, the Harry Weaver Award from the National Multiple Sclerosis Society.

Gayathri Ramaswamy

Gayathri Ramaswamy
Lab Head, Internal Medicine Research Unit
Pfizer
Gayathri Ramaswamy
Lab Head, Internal Medicine Research Unit
Pfizer
 
About Speaker:

Dr. Gayathri Ramaswamy is the head of Lipids and Lysosomes lab and Senior Principal Scientist in the Internal Medicine Research Unit at Pfizer Inc. Dr. Ramaswamy obtained her Ph.D. from St. Jude Children's Research Hospital, University of Tennessee (Memphis) and did her post-doctoral training at Gladstone Institute of Neurological Diseases, University of California (San Francisco). She has more than 18 years of experience in lipid metabolism and is considered an expert in apolipoprotein E (apoE) and its role in Alzheimer's disease. Dr. Ramaswamy has made seminal contributions to understanding the underlying mechanism(s) by which apoE4 contributes to AD. Additionally, she is an expert in small molecule phenotypic screen deconvolution, molecular biology and cell biology. She has also developed reagents for identifying bio-threat agents and for evaluating target gene expression. She has co-authored several peer-reviewed publications. Currently, Dr. Ramaswamy is leading drug discovery programs for treating Alzheimer's disease and Parkinson's disease respectively. Areas of research in her laboratory include understanding the underlying mechanisms that regulate apoE in the brain, mechanistic role of apoE4 in AD, and interrogating the role of lipids and lysosome dysfunction in neurodegenerative diseases.

Sharon Rosenzweig-Lipson

Sharon Rosenzweig-Lipson
Vice President of R&D
Agenebio
Sharon Rosenzweig-Lipson
Vice President of R&D
Agenebio
 
James Salzer

James Salzer
Professor, Department of Neuroscience and Physiology
NYU School of Medicine
James Salzer
Professor, Department of Neuroscience and Physiology
NYU School of Medicine
 
Malu Tansey

Malu Tansey
Associate Professor, Physiology
Emory University
Malu Tansey
Associate Professor, Physiology
Emory University
 
Cheryl Wellington

Cheryl Wellington
Clinical Professor, Djavad Mowafaghian Centre for Brain Health
University of British Columbia
Cheryl Wellington
Clinical Professor, Djavad Mowafaghian Centre for Brain Health
University of British Columbia
 
Michael Yeaman

Michael Yeaman
Professor of Medicine, David Geffen School of Medicine
UCLA
Michael Yeaman
Professor of Medicine, David Geffen School of Medicine
UCLA
 
CNS Partnering & Deal-Making
DISTINGUISHED SPEAKERS
Mark Allegreta

Mark Allegreta
Associate VP, Commercial Research
National Multiple Sclerosis Society
Mark Allegreta
Associate VP, Commercial Research
National Multiple Sclerosis Society
 
Kevin Bitterman

Kevin Bitterman
Partner
Atlas Venture
Kevin Bitterman
Partner
Atlas Venture
 
Christine Brennan

Christine Brennan
Partner
MRL Ventures Fund
Christine Brennan
Partner
MRL Ventures Fund
 
About Speaker:

Dr. Brennan joined MRL Ventures Fund in June 2017. Prior to joining MRL Ventures Fund she spent 3 years as Principal at Novartis Venture Fund (NVF). Prior to NVF, she spent 3 years at Vitae Pharmaceuticals as Chief Business Officer responsible for strategy & business development. Prior to Vitae, she spent 5 years at Novartis Institutes for BioMedical Research in Strategic Alliances, most recently as Executive Director and Head of Strategy & Operations. Prior to Novartis, she held positions in business development and marketing at the biopharmaceutical companies, EnVivo Pharmaceuticals (now FORUM Pharmaceuticals), Biovail (now Valeant Pharmaceuticals) and Cogent Neuroscience. In addition, she was Director at Fidelity Biosciences Group (now F-Prime Capital Partners), a venture capital company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

Charles Duncan

Charles Duncan
Managing Director, Senior Analyst, Equity Research/Emerging Biopharma
Piper Jaffray
Charles Duncan
Managing Director, Senior Analyst, Equity Research/Emerging Biopharma
Piper Jaffray
 
Joseph Foss

Joseph Foss
Founder
NeuroTherapia
Joseph Foss
Founder
NeuroTherapia
 
David Glass

David Glass
Licensing Manager
Innovation Partners Healthcare
David Glass
Licensing Manager
Innovation Partners Healthcare
 
About Speaker:

David Glass is an independent consultant with over thirty years' experience in biotechnology and related life sciences fields, with much of that time devoted to patents, licensing and technology transfer. Dr. Glass has served as associate director of the tech transfer office at Massachusetts General Hospital, and has also managed technology transfer as a consultant or part-time employee at other academic institutions including McLean Hospital, Joslin Diabetes Center, and Baystate Medical Center. Since 2014, he has directed tech transfer as a consultant at the University of Massachusetts at Dartmouth, and he recently completed a one-year assignment as interim licensing manager at Partners HealthCare Innovation, managing and licensing neuroscience and psychiatric technologies from McLean Hospital and the MGH Psychiatry Department. Dr. Glass has also consulted for several other academic institutions and life sciences companies on various aspects of technology licensing and academic-industry partnering., He is a longstanding member of LES and AUTM, and was awarded the Certified Licensing Professional certification in July 2008 (recertified July 2011, expired June 2014) and the Registered Technology Transfer Professional certification in November 2013 (active). He holds a B.S. from Cornell University and a Ph.D. from Princeton University.

Linda Hedley

Linda Hedley
President
Hedley Consulting
Linda Hedley
President
Hedley Consulting
 
Daniel Klamer

Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
 
About Speaker:

Dr Daniel Klamer, Vice President of Business Development and Scientific Strategy of Anavex, has more than 15 years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the USA. Prior to Anavex he worked at e.g. Retrophin and NeuroSearch. At NeuroSearch, Dr Klamer led and evaluated multiple discovery-phase neuropharmacological research products with an emphasis on strategic evaluation of preclinical and clinical development and commercialization.

Dr. Klamer earned his PhD in Pharmacology at The Sahlgrenska Academy at University of Gothenburg, Sweden, his MBA at Fordham Gabelli School of Business, and his Post-Doctoral training at the Department of Psychiatry, Yale University School of Medicine. In addition, Dr. Klamer holds a position as an Associate Professor at the Department of Pharmacology, at The Sahlgrenska Academy at the University of Gothenburg.

Parag Mehta

Parag Mehta
Chief Executive Officer
Aveta Biomics
Parag Mehta
Chief Executive Officer
Aveta Biomics
 
Kiran Reddy

Kiran Reddy
Partner
Clarus Ventures
Kiran Reddy
Partner
Clarus Ventures
 
Nadim Shohdy

Nadim Shohdy
Office of Therapeutics Alliances
NYU
Nadim Shohdy
Office of Therapeutics Alliances
NYU
 
About Speaker:

Dr. Shohdy is an Assistant Dean at NYU School of Medicine, and is both the co-founder and Director of its Office Therapeutics Alliances (OTA), a drug discovery accelerator that utilizes a novel "virtual biotech" approach to help advance NYU biomedical research to a far more validated stage to enable greater quality dealmaking with biopharma and investors. Since its inception in 2013, OTA has transformed the way NYU de-risks its therapeutic projects, currently has a pipeline of over 15 projects, and 7 of its projects have been successfully partnered with biopharma or investors to launch new startups. He received his PhD with Distinction in Microbiology from Columbia University, and completed his postdoctoral training at the Rockefeller University.

Nilufer Tanner

Nilufer Tanner
Professor of Neurology
Mayo Clinic Florida
Nilufer Tanner
Professor of Neurology
Mayo Clinic Florida
 
Iva Toudjarska

Iva Toudjarska
Principal Consultant
Halloran Consulting Group
Iva Toudjarska
Principal Consultant
Halloran Consulting Group